UK clinical trials - updated daily from ClinicalTrials.gov
Find clinical trials for migraine in the United Kingdom. Explore treatment pathways including CGRP inhibitors, Botox, and novel acute and preventive therapies.
Migraine affects ~10 million people in the UK (~15% of the population). It is much more than a headache - causing intense head pain, nausea, sensitivity to light and sound, and sometimes visual disturbances (aura). Chronic migraine (≥15 days/month) affects ~2% of the population and is one of the most disabling conditions globally. It is the 6th highest cause of years lost to disability worldwide.
CGRP (calcitonin gene-related peptide) inhibitors have transformed migraine treatment. Preventive CGRP antibodies: erenumab (Aimovig), fremanezumab (Ajovy), galcanezumab (Emgality) - monthly or quarterly injections. NICE recommends these for chronic or episodic migraine after 3+ preventive medication failures. Acute CGRP antagonists (gepants): rimegepant (Piqray), atogepant - oral tablets that stop migraine attacks without causing medication overuse headache.
Acute treatments: triptans (sumatriptan, rizatriptan) for attacks, combined with NSAIDs. Preventive treatments: beta-blockers (propranolol), antidepressants (amitriptyline), anticonvulsants (topiramate), or CGRP antibodies. For chronic migraine: Botox (onabotulinumtoxinA, 31 injections every 12 weeks) - NICE approved. Newer options: neuromodulation devices (Cefaly, gammaCore) and CGRP gepants.
Active UK migraine trials include: next-generation CGRP inhibitors with longer dosing intervals, dual-action gepants, novel preventive targets (PACAP, oxytocin), precision medicine approaches, neuromodulation devices, and digital therapies. The National Migraine Centre and NHS headache clinics are key trial sites.
We'll email you when new UK clinical trials start recruiting. Free, and you can unsubscribe anytime.
Free AI-powered matching - no signup required
